The DSC2 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line, engineered to harbor a targeted disruption of the desmocollin-2 (DSC2) gene. This loss-of-function model enables investigation of DSC2-dependent processes in epithelial tumor cells without assertions of clonality or complete ablation. The polyclonal format captures a spectrum of editing outcomes, providing a biologically relevant system for studying desmosomal adhesion and its downstream effects in a cancer context.
The A2780 host cell line was established from the primary tumor of an untreated patient with ovarian endometrioid adenocarcinoma and retains wild-type TP53 status. These epithelial cells exhibit characteristics typical of ovarian carcinoma and serve as a widely utilized platform for examining ovarian cancer biology, including cell adhesion, signal transduction, and chemotherapeutic responses. The combination of native desmosomal component expression and epithelial morphology makes A2780 cells particularly suitable for evaluating the functional consequences of desmosome gene disruption.
DSC2 encodes a calcium-dependent cadherin that, together with desmogleins and other desmocollins, constitutes the adhesive core of desmosomes. It interacts with armadillo proteins such as plakoglobin (JUP) and plakophilins (PKP1-3), which in turn anchor desmoplakin (DSP) and intermediate filament networks composed of keratins 8/18. DSC2 functions downstream of transcriptional repressors SNAI1/Snail, SNAI2/Slug, ZEB1, and TWIST1, and its loss can alter Wnt/??-catenin signaling through plakoglobin redistribution, potentially affecting downstream targets like cyclin D1. The desmosomal complex thereby couples intercellular adhesion to cytoskeletal organization and gene expression programs governing epithelial-mesenchymal transition (EMT).
In the context of A2780 ovarian carcinoma cells, disruption of DSC2 is expected to compromise cell-cell adhesion, fostering a more migratory and invasive phenotype that mimics aspects of cancer progression. This model provides a clinically relevant backdrop for dissecting how desmosome dysfunction contributes to ovarian tumor metastasis and for exploring crosstalk between adhesion complexes and EMT regulators. The polyclonal population may recapitulate heterogeneous responses observed in tumors, making it valuable for drug sensitivity and mechanistic studies.
Researchers can employ this knockout product in diverse assays to probe desmosomal biology and ovarian cancer pathophysiology. Western blotting and immunofluorescence detect DSC2 ablation and assess desmosome integrity; cell adhesion and wound healing assays quantify intercellular attachment and motility; transwell migration/invasion assays evaluate metastatic potential; RT-qPCR monitors EMT markers; flow cytometry examines cell cycle and apoptosis; Wnt/??-catenin reporter and co-immunoprecipitation experiments elucidate signaling rewiring. For further details, please contact Ascent Research.
